Dose range
2.5 → 15 mg/wk
Route
Subcutaneous injection, once weekly
Indication(s)
Type 2 diabetes

Titration schedule

StepDoseDurationNotes
12.5 mgWeeks 1-4No glycemic control
25 mg4+ weeksMaintenance option
37.5 mg4+ weeks
410 mg4+ weeksMaintenance option
512.5 mg4+ weeks
615 mgMax

Important notes

  • This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
  • FDA-approved label dosing.
  • Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. FDA has warned compounders that used salt forms (semaglutide sodium and semaglutide acetate), which are not the active ingredient in any approved drug.

References

  1. Mounjaro (brand tirzepatide) prescribing information / clinical literature.
  2. FDA, bulk drug substances used in compounding under section 503A (interim categories), accessed October 2026.
  3. USP <797>: Pharmaceutical Compounding — Sterile Preparations.